This product is intended for research use only and is not suitable for human or veterinary use. The material is tested for solubility in methanol at 50 mg/mL. For use in animal models, various sources note that this compound may be dissolved in DMSO at 25 mg/mL and diluted further with aqueous buffers. Filter sterilization is required.
K2628
Ketotifen fumarate salt
≥99% (TLC), powder, H₁ histamine receptor antagonist
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Size/SKU | Availability | Price |
|---|---|---|
100 mg | Please contact Customer Service for Availability | €43.20 |
1 g | Please contact Customer Service for Availability | €222.00 |
About This Item
Empirical Formula (Hill Notation):
C19H19NOS · C4H4O4
CAS Number:
Molecular Weight:
425.50
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
252-100-0
MDL number:
Form:
powder
Product Name
Ketotifen fumarate salt,
form
powder
Quality Segment
originator
Novartis
SMILES string
OC(=O)\C=C\C(O)=O.CN1CCC(\CC1)=C2/c3ccccc3CC(=O)c4sccc24
InChI
1S/C19H19NOS.C4H4O4/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19;5-3(6)1-2-4(7)8/h2-5,8,11H,6-7,9-10,12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
InChI key
YNQQEYBLVYAWNX-WLHGVMLRSA-N
Gene Information
human ... HRH1(3269), PDE7B(27115)
General description
Ketotifen fumarate salt is an antihistamine drug.
Application
Ketotifen fumarate salt has been used: for mast cell product antagonism, as a positive control in β-hexosaminidase release assay, as mast cell stabilizer to treat pregnant dams added to ad libitum drinking water
Biochem/physiol Actions
H1 histamine receptor antagonist.
Ketotifen fumarate plays a key role in preventing histamine release by blocking the histamine H1 receptors. It interferes with the release of histamine, serotonin and other inflammatory mediators from mast cells. It exhibits with anti-allergic activity, anti-inflammatory effects including mast cell stabilization. It has been widely used for ophthalmic allergic conjunctivitis.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
This Item | |||
|---|---|---|---|
| description - | description European Pharmacopoeia (EP) Reference Standard | description - | description ≥99% (perchloric acid titration) |
| form powder | form - | form powder | form powder |
| Quality Level 100 | Quality Level - | Quality Level 200 | Quality Level 100 |
| originator Novartis | originator - | originator Sanofi Aventis | originator Bayer |
| Gene Information human ... HRH1(3269), PDE7B(27115) | Gene Information human ... HRH1(3269) | Gene Information human ... HRH1(3269) | Gene Information human ... HRH1(3269) |
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
-
En qué se debe disolver este producto para volverlo una dilución inyectable? Se puede en suero fisiológico?
1 answer-
Helpful?
-